期刊
MOLECULES
卷 18, 期 12, 页码 14726-14738出版社
MDPI
DOI: 10.3390/molecules181214726
关键词
baicalein; Parkinson's disease; 6-hydroxydopamine; SH-SY5Y cells; brain mitochondria
资金
- National Natural Science Foundation of China [30973889]
- Science and Technology Major Projects: Significant New-Drugs Creation [2012ZX09103101-078, 2012ZX09103201-042, 2011ZX09401-014]
- Research Special Fund for Public Welfare Industry of Health [200902008]
Parkinson's disease (PD) is a neurodegenerative disorder characterized by progressive loss of dopaminergic (DA) neurons at the substantia nigra. Mitochondrial dysfunction is involved in the mechanism of cell damage in Parkinson's disease (PD). 6-Hydroxydopamine (6-OHDA) is a dopamine analog which specifically damages dopaminergic neurons. Baicalein has been previously reported to have potential in the treatment of PD. The purpose of the present study was to investigate the mechanism of action of baicalein against 6-OHDA injury in SH-SY5Y cells. The results showed that baicalein significantly alleviated alterations of mitochondrial redox activity and mitochondrial membrane potential induced by 6-OHDA in a dose-dependent manner in SH-SY5Y cells compared with vehicle group. Futhermore, baicalein decreased the production of ROS and upregulated the DJ-1 protein expression in SH-SY5Y cells. In addition, baicalein also inhibited ROS production and lipid peroxidation (IC50 = 6.32 +/- 0.03 mu M) in rat brain mitochondia. In summary, the underlying mechanisms of baicalein against 6-OHDA-induced mitochondrial dysfunction may involve inhibition of mitochondrial oxidation and upregulation of DJ-1 protein expression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据